NOTRELOAD AI
  • NOTRELOAD AI
  • Invest ↗
  • myNOTRELOAD (BETA)
  • XY Feed
  • 24-HOUR Pass →
Sign in Subscribe

I-Mab's Givastomig: A Potential Game Changer for Stomach Cancer Treatment

I-Mab's givastomig is a unique immune-boosting drug for stomach cancer, expected to outperform competitors, according to Leerink.

I-Mab's Givastomig: A Potential Game Changer for Stomach Cancer Treatment
Credit: I-Mab
Already have an account? Sign in.
10/03/2025 · 7:07 AM
IMAB
/ Don’t stop at just one post.

Related↓

US Considers Major Curbs on Chinese Medicines
09/10/2025 · 3:00 PM

US Considers Major Curbs on Chinese Medicines

US may curb Chinese drugs over national security fears, with stricter reviews for deals/data. I-Mab stock fell but is a US firm. China's biotech role is growing. White House denies active consideration of draft order.

/ Subscriber only
/ Read more

Feed↓

SB Energy’s IPO: SoftBank Control, OpenAI Campuses, and NVIDIA’s $3 Billion Check
Featured/ 09/21/2026 · 1:19 PM

SB Energy’s IPO: SoftBank Control, OpenAI Campuses, and NVIDIA’s $3 Billion Check

NVIDIA is putting $3B into SB Energy around the IPO and backing part of the Ohio campus if OpenAI fails.

/ Subscriber only
Grail Stock Jumps as FDA Papers Signal Galleri Panel Path
09/21/2026 · 11:55 AM

Grail Stock Jumps as FDA Papers Signal Galleri Panel Path

FDA posted Galleri briefing papers with no leftover lab-test questions. Panel meets Sept. 23; approval odds remain in focus.

/ Subscriber only
Navitas Invests $5 Million in Magnachip to Deepen SiC Partnership
09/21/2026 · 11:39 AM

Navitas Invests $5 Million in Magnachip to Deepen SiC Partnership

Navitas will buy 1.46M Magnachip shares at $3.42 for $5M. The deal builds on their July 2026 silicon carbide pact for high-voltage power chips.

/ Subscriber only
  • UP↑
  • Terms/Privacy
  • Sign up
  • Sign in
  • Discord
  • X
  • Bluesky
  • Telegram
  • Reach out →
  • Invest ↗
  • NOTRELOAD AI
DON'T FALL BEHIND. ©2025
Email address Subscribe